EGFR and neoplasm: Interestingly, other comutant alterations included additional alterations in NRAS in 1 tumor, a rare A18T mutation (7.1%); PIK3CA in 2 tumors (16.7%); and EGFR in 1 tumor, also a rare D761N mutation (7.1%).